Navigation Links
Champions Oncology Reports Financial Results for the Quarter Ended October 31, 2012
Date:12/13/2012

y.

Operating ResultsPersonalized Oncology Solutions (POS) revenues were $0.5 million and $0.6 million for the three months ended October 31, 2012 and 2011, respectively, a decrease of $0.1 million, or 17%. For the six months ended October 31, 2012 and 2011, POS revenues were $1.4 million and $1.2 million, respectively, an increase of $0.2 million, or 17%. The increase in POS revenues was driven by an increased number of drug studies completed during the six months ended October 31, 2012 compared to the same period in the previous year. During the six months ended October 31, 2012 and 2011, the Company completed 22 and 5 drug studies, respectively.  These increases are the result of the steady increase in the number of TumorGrafts performed which have moved onto drug studies.

POS cost of sales was $0.6 million and $0.5 million for the three months ended October 31, 2012 and 2011, respectively, an increase of $0.1 million, or 20%. For the six months ended October 31, 2012 and 2011, POS cost of sales was $1.4 million and $0.9 million, respectively, an increase of $0.5 million, or 56%. For the three months ended October 31, 2012 and 2011, gross margins for POS were -20% and 17%, respectively. For the six months ended October 31, 2012 and 2011, gross margins for POS were 0% and 25%, respectively.  The increases in cost of sales and the declines in gross margins can be attributed to increased volumes of implants and drug studies performed, in line with management's strategy to obtain more tumors to increase our tumor model offerings to our TOS sponsors and increase the number of models in our Tumorbank 

Translational Oncology Solutions (TOS) revenues were $1.0 million and $1.2 million for the three months ended October 31, 2012 and 2011, respectively, a decrease of $0.2 million, or 17%. The decrease in TOS revenues was due primarily to decreased contract bookings in the previous quarters. TOS revenues were $2.2 million for each of the
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
2. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
3. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
8. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
9. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
10. International Oncology Innovators Meeting in Hamburg
11. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... today (August 22nd), in the scientific journal ... Programme establish the effect of serotonin on sensitivity ... and optical techniques., "Serotonin is a small molecule ... of brain functions, from the control of sleep ... behaviours, This neurotransmitter is also popularly thought to ...
(Date:8/22/2014)... Ophthalmic drug delivery technologies or ... endeavors as the anatomy, physiology and biochemistry of ... foreign substances. Ocular drug delivery technologies provide several ... minimal use of needles; also it enables high ... specific targeting within the ocular globe. On the ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - ... The global molecular biology enzymes market was ... to grow at a CAGR of 13.74% to reach ... reagents find applications in a large number of fields ...
(Date:8/22/2014)... 22, 2014 The identification of ... can be accelerated by exome sequencing. Built on ... the custom SeqCap EZ Developer system has been ... Watson will additionally present how he achieved coverage ... human and mouse exome kits. With over 236,000 ...
Breaking Biology Technology:From happiness to pain: Understanding serotonin's function 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2
... provides the Company and investor an option to sell or ... purchase additional $67.5 million in securities, SEATTLE, April ... CTIC ; MTA) today announced that it has,entered into agreements ... Series E Convertible Preferred Stock (the "Preferred,Stock"), 13.5% Convertible Senior ...
... 29 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... discuss first quarter 2008 financial,results and provide a general ... Eastern Time (2:00 p.m. Pacific Time). Financial results for ... earlier that day., Interested parties may access a ...
... SOUTH SAN FRANCISCO, Calif., April 29 ,Anesiva, Inc. ... exclusive Zingo(TM),marketing and distribution agreement, with Green Vision ... powder intradermal injection system is approved in the ... IV insertions or blood,draws in children three to ...
Cached Biology Technology:Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor 2Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor 3Anesiva Announces New Zingo Marketing and Distribution Agreement 2Anesiva Announces New Zingo Marketing and Distribution Agreement 3
(Date:8/21/2014)... Aug. 21, 2014 Nxt-ID, Inc. (OTCQB: NXTD), ... commerce market, announced today that its shares of common ... be issued in its proposed underwritten public offering of ... on The Nasdaq Capital Market, subject to closing of ... and warrants, and will trade under the symbol "NXTD" ...
(Date:8/21/2014)... dandruff, eczema and other itchy, flaky maladies in humans ... Hawaiian coral reefs and the extreme environments of arctic ... the scientific journal PLOS Pathogens considers the ... genus Malassezia in light of new insights ... world. , University of Hawai,i at Mānoa scientist Anthony ...
(Date:8/21/2014)... researchers from Beth Israel Deaconess Medical Center (BIDMC ) ... Most Influential Scientific Minds 2014," a comprehensive list ... web resource for science metrics and research performance analysis. ... most influential "are performing and publishing work that their ... science," according to a Thomson Reuters statement. Researchers were ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... at the Virginia Bioinformatics Institute and Duke University ... appears to play an important role in the ... brassicicola, a destructive fungal pathogen that causes black ... results in considerable leaf loss in many economically ...
... practice of killing wild badgers to prevent tuberculosis in ... led by Rosie Woodroffe, an ecologist at the University ... Group on Cattle TB. , In Britain, farming interests ... the merits of culling badgers to fight cattle tuberculosis, ...
... life--large, small, and microscopic. Bacteriophage (phage) viruses are minute, ... their communities through predation and parasitism. Despite their small ... of them in a bucket full of seawater as ... they can have a huge impact ecologically. , ...
Cached Biology News:Tearing down the fungal cell wall 2Tearing down the fungal cell wall 3British cattle give TB to badgers, finds UC Davis expert 2Hundreds of thousands of viral species present in the world's oceans 2
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
... A thermostable, thermoactive designer enzyme ... single-tube-reaction. AccuRT RNA PCR enzyme allows ... be performed at elevated temperatures (65C), ... from the template and results in ...
Request Info...
EML1 (K-16)...
Biology Products: